Inhibition of Metabolic Shift can Decrease Therapy Resistance in Human High-Grade Glioma Cells

Gábor Petővári, Titanilla Dankó, Ildikó Krencz, Zoltán Hujber, Hajnalka Rajnai, Enikő Vetlényi, Regina Raffay, Judit Pápay, A. Jeney, A. Sebestyén

Research output: Article

Abstract

The high-grade brain malignancy, glioblastoma multiforme (GBM), is one of the most aggressive tumours in central nervous system. The developing resistance against recent therapies and the recurrence rate of GBMs are extremely high. In spite several new ongoing trials, GBM therapies could not significantly increase the survival rate of the patients as significantly. The presence of inter- and intra-tumoral heterogeneity of GBMs arise the problem to find both the pre-existing potential resistant clones and the cellular processes which promote the adaptation mechanisms such as multidrug resistance, stem cell-ness or metabolic alterations, etc. In our work, the in situ metabolic heterogeneity of high-grade human glioblastoma cases were analysed by immunohistochemistry using tissue-microarray. The potential importance of the detected metabolic heterogeneity was tested in three glioma cell lines (grade III-IV) using protein expression analyses (Western blot and WES Simple) and therapeutic drug (temozolomide), metabolic inhibitor treatments (including glutaminase inhibitor) to compare the effects of rapamycin (RAPA) and glutaminase inhibitor combinations in vitro (Alamar Blue and SRB tests). The importance of individual differences and metabolic alterations were observed in mono-therapeutic failures, especially the enhanced Rictor expressions after different mono-treatments in correlation to lower sensitivity (temozolomide, doxycycline, etomoxir, BPTES). RAPA combinations with other metabolic inhibitors were the best strategies except for RAPA+glutaminase inhibitor. These observations underline the importance of multi-targeting metabolic pathways. Finally, our data suggest that the detected metabolic heterogeneity (the high mTORC2 complex activity, enhanced expression of Rictor, p-Akt, p-S6, CPT1A, and LDHA enzymes in glioma cases) and the microenvironmental or treatment induced metabolic shift can be potential targets in combination therapy. Therefore, it should be considered to map tissue heterogeneity and alterations with several cellular metabolism markers in biopsy materials after applying recently available or new treatments.

Original languageEnglish
JournalPathology and Oncology Research
DOIs
Publication statusPublished - jan. 1 2019

Fingerprint

Glioma
temozolomide
Glutaminase
Sirolimus
Glioblastoma
Therapeutics
Inhibition (Psychology)
S 6
Central Nervous System Neoplasms
Doxycycline
Multiple Drug Resistance
Metabolic Networks and Pathways
Individuality
Stem Cells
Survival Rate
Clone Cells
Western Blotting
Immunohistochemistry
Biopsy
Recurrence

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Oncology
  • Cancer Research

Cite this

Inhibition of Metabolic Shift can Decrease Therapy Resistance in Human High-Grade Glioma Cells. / Petővári, Gábor; Dankó, Titanilla; Krencz, Ildikó; Hujber, Zoltán; Rajnai, Hajnalka; Vetlényi, Enikő; Raffay, Regina; Pápay, Judit; Jeney, A.; Sebestyén, A.

In: Pathology and Oncology Research, 01.01.2019.

Research output: Article

Petővári, Gábor ; Dankó, Titanilla ; Krencz, Ildikó ; Hujber, Zoltán ; Rajnai, Hajnalka ; Vetlényi, Enikő ; Raffay, Regina ; Pápay, Judit ; Jeney, A. ; Sebestyén, A. / Inhibition of Metabolic Shift can Decrease Therapy Resistance in Human High-Grade Glioma Cells. In: Pathology and Oncology Research. 2019.
@article{b7b4cdf467ad46eeb9206516e99b9c14,
title = "Inhibition of Metabolic Shift can Decrease Therapy Resistance in Human High-Grade Glioma Cells",
abstract = "The high-grade brain malignancy, glioblastoma multiforme (GBM), is one of the most aggressive tumours in central nervous system. The developing resistance against recent therapies and the recurrence rate of GBMs are extremely high. In spite several new ongoing trials, GBM therapies could not significantly increase the survival rate of the patients as significantly. The presence of inter- and intra-tumoral heterogeneity of GBMs arise the problem to find both the pre-existing potential resistant clones and the cellular processes which promote the adaptation mechanisms such as multidrug resistance, stem cell-ness or metabolic alterations, etc. In our work, the in situ metabolic heterogeneity of high-grade human glioblastoma cases were analysed by immunohistochemistry using tissue-microarray. The potential importance of the detected metabolic heterogeneity was tested in three glioma cell lines (grade III-IV) using protein expression analyses (Western blot and WES Simple) and therapeutic drug (temozolomide), metabolic inhibitor treatments (including glutaminase inhibitor) to compare the effects of rapamycin (RAPA) and glutaminase inhibitor combinations in vitro (Alamar Blue and SRB tests). The importance of individual differences and metabolic alterations were observed in mono-therapeutic failures, especially the enhanced Rictor expressions after different mono-treatments in correlation to lower sensitivity (temozolomide, doxycycline, etomoxir, BPTES). RAPA combinations with other metabolic inhibitors were the best strategies except for RAPA+glutaminase inhibitor. These observations underline the importance of multi-targeting metabolic pathways. Finally, our data suggest that the detected metabolic heterogeneity (the high mTORC2 complex activity, enhanced expression of Rictor, p-Akt, p-S6, CPT1A, and LDHA enzymes in glioma cases) and the microenvironmental or treatment induced metabolic shift can be potential targets in combination therapy. Therefore, it should be considered to map tissue heterogeneity and alterations with several cellular metabolism markers in biopsy materials after applying recently available or new treatments.",
keywords = "Combination therapy, Glioma, Metabolic shift, Metabolism, mTORC2",
author = "G{\'a}bor Petőv{\'a}ri and Titanilla Dank{\'o} and Ildik{\'o} Krencz and Zolt{\'a}n Hujber and Hajnalka Rajnai and Enikő Vetl{\'e}nyi and Regina Raffay and Judit P{\'a}pay and A. Jeney and A. Sebesty{\'e}n",
year = "2019",
month = "1",
day = "1",
doi = "10.1007/s12253-019-00677-2",
language = "English",
journal = "Pathology and Oncology Research",
issn = "1219-4956",
publisher = "Springer Netherlands",

}

TY - JOUR

T1 - Inhibition of Metabolic Shift can Decrease Therapy Resistance in Human High-Grade Glioma Cells

AU - Petővári, Gábor

AU - Dankó, Titanilla

AU - Krencz, Ildikó

AU - Hujber, Zoltán

AU - Rajnai, Hajnalka

AU - Vetlényi, Enikő

AU - Raffay, Regina

AU - Pápay, Judit

AU - Jeney, A.

AU - Sebestyén, A.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - The high-grade brain malignancy, glioblastoma multiforme (GBM), is one of the most aggressive tumours in central nervous system. The developing resistance against recent therapies and the recurrence rate of GBMs are extremely high. In spite several new ongoing trials, GBM therapies could not significantly increase the survival rate of the patients as significantly. The presence of inter- and intra-tumoral heterogeneity of GBMs arise the problem to find both the pre-existing potential resistant clones and the cellular processes which promote the adaptation mechanisms such as multidrug resistance, stem cell-ness or metabolic alterations, etc. In our work, the in situ metabolic heterogeneity of high-grade human glioblastoma cases were analysed by immunohistochemistry using tissue-microarray. The potential importance of the detected metabolic heterogeneity was tested in three glioma cell lines (grade III-IV) using protein expression analyses (Western blot and WES Simple) and therapeutic drug (temozolomide), metabolic inhibitor treatments (including glutaminase inhibitor) to compare the effects of rapamycin (RAPA) and glutaminase inhibitor combinations in vitro (Alamar Blue and SRB tests). The importance of individual differences and metabolic alterations were observed in mono-therapeutic failures, especially the enhanced Rictor expressions after different mono-treatments in correlation to lower sensitivity (temozolomide, doxycycline, etomoxir, BPTES). RAPA combinations with other metabolic inhibitors were the best strategies except for RAPA+glutaminase inhibitor. These observations underline the importance of multi-targeting metabolic pathways. Finally, our data suggest that the detected metabolic heterogeneity (the high mTORC2 complex activity, enhanced expression of Rictor, p-Akt, p-S6, CPT1A, and LDHA enzymes in glioma cases) and the microenvironmental or treatment induced metabolic shift can be potential targets in combination therapy. Therefore, it should be considered to map tissue heterogeneity and alterations with several cellular metabolism markers in biopsy materials after applying recently available or new treatments.

AB - The high-grade brain malignancy, glioblastoma multiforme (GBM), is one of the most aggressive tumours in central nervous system. The developing resistance against recent therapies and the recurrence rate of GBMs are extremely high. In spite several new ongoing trials, GBM therapies could not significantly increase the survival rate of the patients as significantly. The presence of inter- and intra-tumoral heterogeneity of GBMs arise the problem to find both the pre-existing potential resistant clones and the cellular processes which promote the adaptation mechanisms such as multidrug resistance, stem cell-ness or metabolic alterations, etc. In our work, the in situ metabolic heterogeneity of high-grade human glioblastoma cases were analysed by immunohistochemistry using tissue-microarray. The potential importance of the detected metabolic heterogeneity was tested in three glioma cell lines (grade III-IV) using protein expression analyses (Western blot and WES Simple) and therapeutic drug (temozolomide), metabolic inhibitor treatments (including glutaminase inhibitor) to compare the effects of rapamycin (RAPA) and glutaminase inhibitor combinations in vitro (Alamar Blue and SRB tests). The importance of individual differences and metabolic alterations were observed in mono-therapeutic failures, especially the enhanced Rictor expressions after different mono-treatments in correlation to lower sensitivity (temozolomide, doxycycline, etomoxir, BPTES). RAPA combinations with other metabolic inhibitors were the best strategies except for RAPA+glutaminase inhibitor. These observations underline the importance of multi-targeting metabolic pathways. Finally, our data suggest that the detected metabolic heterogeneity (the high mTORC2 complex activity, enhanced expression of Rictor, p-Akt, p-S6, CPT1A, and LDHA enzymes in glioma cases) and the microenvironmental or treatment induced metabolic shift can be potential targets in combination therapy. Therefore, it should be considered to map tissue heterogeneity and alterations with several cellular metabolism markers in biopsy materials after applying recently available or new treatments.

KW - Combination therapy

KW - Glioma

KW - Metabolic shift

KW - Metabolism

KW - mTORC2

UR - http://www.scopus.com/inward/record.url?scp=85067418287&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85067418287&partnerID=8YFLogxK

U2 - 10.1007/s12253-019-00677-2

DO - 10.1007/s12253-019-00677-2

M3 - Article

AN - SCOPUS:85067418287

JO - Pathology and Oncology Research

JF - Pathology and Oncology Research

SN - 1219-4956

ER -